Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Sapablursen in Polycythemia Vera
jRCT2071260061Phase 3Not yet recruiting
- Sponsor
- Study Sponsor: Ono Pharmaceutical Co., Ltd. Authorized Sponsor Representative: Deciphera Pharmaceuti
- Start
- Oct 2026
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Sapablursen arm with Placebo arm (2 arms). Primary endpoint: Percentage of participants with absence of phlebotomy eligibility (Week 20–32). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sapablursen
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on jRCT2071260061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260061.